Oscine Therapeutics
Sana Biotechnology is a science-driven, patient-centric company focused on creating and delivering engineered cells as medicines. Their mission involves repairing and controlling genes, replacing missing or damaged cells, and making therapies broadly accessible to patients. They aim to lead in the development of innovative gene and cell therapies for a wide range of diseases, including cancer, autoimmune disorders, and genetic conditions. Sana collaborates with academic laboratories and industry partners, and operates in Seattle, Cambridge, and South San Francisco.
Industries
Nr. of Employees
small (1-50)
Oscine Therapeutics
188 East Blaine Street Suite 400 Seattle, WA 98102
Products
Allogeneic hypoimmune CD19-directed CAR T therapy (clinical program)
A donor-derived CAR T cell program engineered to target CD19 on B cells and incorporate immune-evasive modifications to reduce host rejection and graft-versus-host risk; studied in a Phase 1 trial for severe relapsed or refractory B-cell–mediated autoimmune diseases.
Allogeneic hypoimmune CD22-directed CAR T therapy (clinical program)
A donor-derived CAR T program engineered to target CD22 on B cells with immune-evasive modifications; studied in a Phase 1 trial for relapsed/refractory B-cell malignancies.
Stem cell-derived pancreatic islet cell therapy (preclinical/first-in-human program)
Differentiated islet-like cells derived from stem cells intended for transplantation to replace insulin-producing cells in type 1 diabetes; includes hypoimmune modifications for immune evasion in some programs.
Glial progenitor and CNS cell therapy programs (acquired technology integration)
Development and integration of glial progenitor cell–based approaches for central nervous system disorders, aiming to translate preclinical programs toward clinical testing.
In vivo targeted delivery and gene-modification program
Preclinical work on in vivo platforms designed to deliver genetic payloads to specific cell types for gene modification or control directly within patients.
Allogeneic hypoimmune CD19-directed CAR T therapy (clinical program)
A donor-derived CAR T cell program engineered to target CD19 on B cells and incorporate immune-evasive modifications to reduce host rejection and graft-versus-host risk; studied in a Phase 1 trial for severe relapsed or refractory B-cell–mediated autoimmune diseases.
Allogeneic hypoimmune CD22-directed CAR T therapy (clinical program)
A donor-derived CAR T program engineered to target CD22 on B cells with immune-evasive modifications; studied in a Phase 1 trial for relapsed/refractory B-cell malignancies.
Stem cell-derived pancreatic islet cell therapy (preclinical/first-in-human program)
Differentiated islet-like cells derived from stem cells intended for transplantation to replace insulin-producing cells in type 1 diabetes; includes hypoimmune modifications for immune evasion in some programs.
Glial progenitor and CNS cell therapy programs (acquired technology integration)
Development and integration of glial progenitor cell–based approaches for central nervous system disorders, aiming to translate preclinical programs toward clinical testing.
In vivo targeted delivery and gene-modification program
Preclinical work on in vivo platforms designed to deliver genetic payloads to specific cell types for gene modification or control directly within patients.
Services
Design and execution of Phase 1 studies including safety monitoring, pharmacokinetics, biomarker collection, and long-term follow-up specific to cell- and gene-based therapeutics.
Collaborative research with academic laboratories and industry partners to advance discovery and translate enabling technologies into therapeutic programs.
Process development, analytical method development, and supply chain planning to support scalable manufacture of cell therapy products.
Regulatory planning and submission support for cell and gene therapy INDs and related interactions with health authorities.
Design and execution of Phase 1 studies including safety monitoring, pharmacokinetics, biomarker collection, and long-term follow-up specific to cell- and gene-based therapeutics.
Collaborative research with academic laboratories and industry partners to advance discovery and translate enabling technologies into therapeutic programs.
Process development, analytical method development, and supply chain planning to support scalable manufacture of cell therapy products.
Regulatory planning and submission support for cell and gene therapy INDs and related interactions with health authorities.
Expertise Areas
- Engineered cell therapy development
- Ex vivo allogeneic CAR T engineering
- In vivo cell engineering and delivery
- Hypoimmune immunoengineering
Key Technologies
- Allogeneic CAR T cell engineering
- Hypoimmune immunoengineering (HLA reduction, innate-immune evasion)
- Stem cell differentiation to islet and glial cell types
- In vivo payload delivery platforms
News & Updates
Sana announced the appointment of Josh Bilenker, Alise Reicin, and Michelle Seitz to its Board of Directors.
Ke Liu joins Sana as Head of Regulatory Affairs & Strategy after more than 17 years at the FDA.
Sana announced the acquisition of Oscine Corp., a company developing therapies for CNS diseases.
Sana added Ed Rebar and Terry Fry to its senior leadership team.
Sana raised over $700 million in its initial financing round.
Stacey Ma joins Sana to oversee process development, supply chain, and manufacturing.
Sana announced the appointment of Josh Bilenker, Alise Reicin, and Michelle Seitz to its Board of Directors.
Ke Liu joins Sana as Head of Regulatory Affairs & Strategy after more than 17 years at the FDA.
Sana announced the acquisition of Oscine Corp., a company developing therapies for CNS diseases.
Sana added Ed Rebar and Terry Fry to its senior leadership team.
Sana raised over $700 million in its initial financing round.
Stacey Ma joins Sana to oversee process development, supply chain, and manufacturing.